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Abstract
Background: The regulation of adult stem cell migration through human hematopoietic tissue involves the chemokine
CXCL12 (SDF-1) and its receptor CXCR4 (CD184). In addition, human leukocyte elastase (HLE) plays a key role. When HLE is
located on the cell surface (HLECS), it acts not as a proteinase, but as a receptor for a1proteinase inhibitor (a1PI, a1antitrypsin,
SerpinA1). Binding of a1PI to HLECS forms a motogenic complex. We previously demonstrated that a1PI deficiency attends
HIV-1 disease and that a1PI augmentation produces increased numbers of immunocompetent circulating CD4
+
lymphocytes. Herein we investigated the mechanism underlying the a1PI deficiency that attends HIV-1 infection.
Methods and Findings: Active a1PI in HIV-1 subjects (median 17 mM, n=35) was significantly below normal (median 36 mM,
p,0.001, n=30). In HIV-1 uninfected subjects, CD4
+ lymphocytes were correlated with the combined factors a1PI, HLECS
+
lymphocytes, and CXCR4
+ lymphocytes (r
2=0.91, p,0.001, n=30),but not CXCL12.In contrast, in HIV-1 subjectswith.220 CD4
cells/ml, CD4
+ lymphocytes were correlated solely with active a1PI (r
2=0.93,p,0.0001, n=26). The monoclonal anti-HIV-1 gp120
antibody 3F5 present in HIV-1 patient blood is shown to bind and inactivate human a1PI. Chimpanzee a1PI differs from human
a1PI by a single amino acid within the 3F5-binding epitope. Unlike human a1PI, chimpanzee a1PI did not bind 3F5 or become
depleted following HIV-1 challenge, consistent with the normal CD4
+ lymphocyte levels and benign syndrome of HIV-1 infected
chimpanzees. The presence of IgG-a1PI immune complexes correlated with decreased CD4
+ lymphocytes in HIV-1 subjects.
Conclusions: This report identifies an autoimmune component of HIV-1 disease that can be overcome therapeutically.
Importantly, results identify an achievable vaccine modification with the novel objective to protect against AIDS as opposed
to the current objective to protect against HIV-1 infection.
Citation: Bristow CL, Babayeva MA, LaBrunda M, Mullen MP, Winston R (2012) a1Proteinase Inhibitor Regulates CD4
+ Lymphocyte Levels and Is Rate Limiting in
HIV-1 Disease. PLoS ONE 7(2): e31383. doi:10.1371/journal.pone.0031383
Editor: Edecio Cunha-Neto, University of Sao Paulo, Brazil
Received September 20, 2011; Accepted January 6, 2012; Published February 17, 2012
Copyright:  2012 Bristow et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Research was supported by the University of North Carolina Center for AIDS Research and Harry Winston Research Foundation. The funders had no role
in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Co-author RW is President of the Institute for Human Genetics and Biochemistry which oversees the Harry Winston Research Foundation
that funds research conducted by lead author CB. CB acts as a research consultant to the Institute. This does not alter the authors’ adherence to all the PLoS ONE
policies on sharing data and materials. All other authors declare no competing interests.
* E-mail: cyb2005@med.cornell.edu
Introduction
Hematopoiesis in humans begins with stem cell migration from
fetal liver through the periphery to the stromal area of
hematopoietic tissue where cells are retained, differentiated, and
released as maturing progenitor cells back into the periphery.
Progenitor cells subsequently migrate to functionally unique tissues
such as thymus for further steps of locally-defined differentiation.
Pools of stem cells and progenitor cells are retained in
hematopoietic tissue throughout life providing a microenviron-
ment for progenitor cell renewal [1]. In human adults,
hematopoiesis is dependent on the chemokine receptor CXCR4
and its ligand CXCL12 with an additional role played by cell
surface human leukocyte elastase (HLECS), and these components
are motogenic [2–4].
Mutations in the HLE-encoding gene ELA2 produce periodic
cycling in hematopoiesis that affect monocytes and neutrophils
[5,6]. HLECS and its granule-released counterpart (HLEG) are
synthesized as a single molecular protein that is trafficked to the
cell surface early in ontogeny and is then redirected by C-terminal
processing to the granule compartment later in ontogeny [7–9].
Generally, HLE mutations that prevent its localization to the
plasma membrane cause cyclic neutropenia, while mutations that
cause exclusive localization to the plasma membrane cause severe
congenital neutropenia [7]. Individuals carrying a mutation in the
transcriptional repressor oncogene GFI1 which targets ELA2,
synthesize twice more HLE, twice fewer absolute numbers of
circulating CD4
+ and CD8
+ lymphocytes, and 7 times more
monocytic cells [10]. Thus, as opposed to the well characterized
enzymatic function of HLEG, the primary functions of HLECS
appear to be cell migration and hematopoiesis [2,4,11].
The physiologic ligand for HLECS is a1proteinase inhibitor
(a1PI, a1antitrypsin, SerpinA1) which is synthesized in hematopoi-
etic and hepatic tissue [12]. Evidence suggests that a1PI also
participates in hematopoiesis, specifically thymopoiesis [13].
During thymopoiesis, a cluster of mouse genes are expressed
sequentially and were previously identified to encode the T cell
alloantigens, Tpre, Tthy, Tind, and Tsu [14]. The chromosomal
location of these maturational markers corresponds to that of a1PI,
and using monoclonal antibodies that discriminate these mouse
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a1PI [15].
The motogenic activities of HLECS and a1PI involve direct or
indirect interaction with Mac-1, an aMb2 integrin [16], and
members of the LDL receptor family [17,18]. In addition, a1PI-
HLECS complexes co-localize with the receptors CD4 and
CXCR4 in polarized cells, an activity that promotes cell migration
and facilitates HIV-1 binding and infectivity [11,19,20]. We and
others have shown that pretreatment of cells with a1PI and other
ligands of HLECS for 60 min inhibits HIV-1 binding and
infectivity [21–23]. In contrast, we have also shown that
pretreatment of cells with a1PI for 15 min facilitates HIV-1
binding and infectivity [19]. These opposing effects of a1PI may be
due to the kinetics of a1PI–induced cell migration which begins
with receptor polarization at the leading edge of the migrating cell
and concludes with endocytosis of the receptor aggregate at the
trailing edge of the cell [18]. After 60 min incubation with a1PI,
the HIV-1 receptor aggregate has been internalized rendering cells
temporally unable to bind to HIV-1 [22,23]. Thus, it is likely that
the principal influence of a1PI on HIV-1 binding and infectivity is
due to its extracellular activities.
Alternative mechanisms of action have been suggested for the
a1PI effect on HIV-1 infectivity including that it is both an
inhibitor of and is a substrate of two proteinases, the HIV-1
aspartyl protease and the host proteinase furin, both of which
participate in processing viral proteins [24]. Like other serine
proteinase inhibitors, a1PI forms an irreversible, covalent-like
complex with its cognate proteinase, HLEG or HLECS, thereby
inhibiting elastolytic activity. The binding of a1PI to the catalytic
site within HLE interrupts the electron transfer mechanism of the
catalytic triad. Cleavage is not completed, and a1PI is not cleaved
[25]. Interaction of a1PI with serine proteinases other than HLE,
for example furin, can produce cleavage, and in this case, a1PI is
acting as a substrate, not an inhibitor [26]. The evidence that a1PI
is a substrate for the HIV-1 aspartyl protease implies a1PI
competes with the protease’s natural substrate (Gag-Pol) such that
the decreased cleavage of Gag-Pol detected was due to substrate
competition, rather than inhibition.
In addition to hepatocytes, a1PI is produced in bone marrow,
by lymphocytic and monocytic cells in lymphoid tissue, and by the
Paneth cells of the gut [27,28]. Since a1PI therapy in our previous
study produced increased CD4 numbers in PIzz as it did in HIV-1
patients, it can be interpreted that a1PI in circulation contributes
to CD4 numbers [13]. Since PIzz patients have very low blood
concentrations of a1PI and do not consistently exhibit below
normal CD4 numbers, it can be interpreted that a1PI produced in
bone marrow and lymphocytic tissue also contribute to regulating
CD4 numbers.
The kinetics of T cell death and proliferation has explained, in
part, the short-term depletion of the circulating pool of CD4
+ T
cells in HIV-1 infection [29]; however, an explanation for their
long-term depletion is absent and involves both depletion of the
circulating pool and depression of hematopoiesis [13,30]. It was
previously demonstrated that in HIV-1 disease, a1PI is severely
deficient suggesting that insufficient a1PI could impede thymopoi-
esis [31]. In a longitudinal study, the number of immunocompe-
tent CD4
+ lymphocytes in HIV-1 subjects was found to increase to
normal levels within 2 weeks of initiating a1PI augmentation
therapy, and this suggests that a1PI participates in regulating the
number of circulating CD4
+ lymphocytes [13]. Herein is shown
that in a cross-sectional study, a1PI correlates with the number of
CD4
+ lymphocytes in HIV-1 subjects. The presence of anti-HIV-1
IgG-a1PI immune complexes in HIV-1 patients is shown to cause
the attendant functional deficiency in a1PI.
Results
Lymphocyte numbers are regulated by a1PI
In healthy individuals, the concentration of a1PI in serum
ranges from 18–53 mM between the 5
th and 95
th percentiles, and
90–100% of this protein is in its active form as determined by
inhibition of porcine pancreatic elastase [31]. To investigate the
relationship between active serum a1PI concentration, HLECS
+,
and CD4
+ lymphocyte numbers, blood was collected from 30
healthy HIV-1 uninfected adults, 14 males and 16 females
(Table 1). Neither serum active a1PI, serum CXCL12, HLECS
+
lymphocytes, or CXCR4
+ lymphocytes, were independently
correlated with CD4
+ lymphocytes. However, using multilinear
regression analysis it was found that higher CD4
+ lymphocytes
were significantly correlated with a combination of factors
including higher serum active a1PI, lower HLECS
+ lymphocyte
numbers, and higher CXCR4
+ lymphocyte numbers (r
2=0.91,
p,0.001). Neither serum CXCL12 (r
2=0.21) nor CCR5
+
lymphocytes (r
2=0.56) were significantly correlated with CD4
+
lymphocytes. Using multilinear regression, absolute lymphocyte
numbers (T B, and NK cells) were correlated with CXCR4
+
lymphocytes (r
2=0.90, p,0.001), but not with HLECS
+ lympho-
cytes, serum active a1PI or serum CXCL12. These results are
consistent with a regulatory pathway for CD4
+ lymphocyte
Table 1. Regression analysis of CD4
+ and absolute lymphocyte numbers in HIV-1 uninfected subjects.
Independent Variables
HLECS
+ Ly CXCR4
+ Ly Active a1PI CXCL12
69±41 cells/ml, n=31
a 2033±683 cells/ml, n=32 26±6 mM, n=36 283±58 pM, n=32
Dependent Variables Multilinear Regression
b
CD4
+ Ly
10246415 cells/ml, n=32
p,0.001 p,0.001 p,0.001 p=0.965 r
2=0.92, p,0.001, n=31
Total Ly
22656746 cells/ml, n=35
p=0.540 p,0.001 p=0.812 p=0.264 r
2=0.91, p,0.001, n=31
aValues for independent and dependent variables represent mean 6 standard deviation. HLECS
+ lymphocytes and CXCR4
+ lymphocytes in the lymphocyte gate (Ly)
were quantitated using flow cytometry. Active a1PI and CXCL12 were quantitated in serum as described.
bMultilinear regression was performed to determine the relationship of the dependent variables to the independent variables using power of test a=0.05. Dependent
variables were considered to be significantly related to the independent variable if they contributed significantly to the multilinear regression (p,0.05). In this
population sample, variables were found to have constant variance and normality.
doi:10.1371/journal.pone.0031383.t001
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HLECS.
a1PI is correlated with CD4
+ lymphocyte numbers in HIV-
1 disease
In the cross-sectional study population, blood was collected
from 35 HIV-1 infected adults, 33 males and 2 females. Of these
35, 26 were found to have .220 CD4 cells/ml and 9 to have ,220
CD4 cells/ml at the time of blood collection. All HIV-1 infected
subjects were measured for numbers of CD4
+, CXCR4
+, and
CCR5
+ lymphocytes, as well as serum concentrations of CXCL12
as well as total, active, and inactive a1PI. Of these 35 subjects, 11
had active liver disease as defined by detectable Hepatitis B or C,
or elevated liver enzymes. HIV-1 infected subjects with liver
disease were not different from HIV-1 infected subjects without
liver disease in serum active a1PI (p=0.95), serum total a1PI
(p=0.79), CXCR4
+ lymphocytes (p=0.63), or CCR5
+ lympho-
cytes (p=0.9), but exhibited significantly higher serum CXCL12
(p,0.001), HLECS
+ lymphocytes (p,0.001), and CD4
+ lympho-
cytes (p=0.04).
In the 26 HIV-1 infected subjects with .220 CD4 cells/ml,
absolute lymphocyte counts were significantly lower in HIV-1
infected subjects than HIV-1 uninfected subjects (p=0.03) as were
CXCR4
+ lymphocytes (p=0.001), CD4
+ lymphocytes (p,0.001),
and active a1PI (p,0.001). On the other hand, total a1PI
(p=0.003) and inactive a1PI (p,0.001) were significantly higher
in HIV-1 infected subjects. In these HIV-1 infected subjects,
higher CD4
+ lymphocyte numbers were correlated with higher
concentration of serum active a1PI (r
2=0.927, p,0.0001) and
lower concentration of serum inactive a1PI (r
2=0.946, p,0.0001)
(Fig. 1A).
Regression analysis revealed a sigmoidal relationship between
CD4
+ lymphocyte numbers and active a1PI or inactive a1PI, and
this is typical of many biological relationships in which a linear
relationship reaches plateau at saturation (Fig. 1A). In contrast, in
HIV-1 uninfected subjects, there was no apparent sigmoidal
relationship between CD4
+ lymphocyte numbers and active a1PI
(r
2=0.20) or inactive a1PI (r
2=0.22), and this is due to the
multiple interacting relationships between CD4
+ lymphocytes and
CXCR4
+ lymphocytes, CXCL12 and active a1PI.
Of these 26 subjects, 21 were additionally measured for HLECS.
As in the HIV-1 uninfected population, HLECS
+ lymphocyte
numbers were not independently correlated with CD4
+ lympho-
cyte numbers, but in combination with higher serum active a1PI
concentration, lower HLECS
+ lymphocytes were significantly
correlated with CD4
+ lymphocyte numbers (p=0.01) (Table 2).
In subjects with ,220 CD4 cells/ml, there was no relationship
between CD4
+ lymphocyte numbers and active or inactive a1PI
concentrations in serum (Fig. 1A), and this suggests either HIV-1
itself, or other host processes contribute to disrupting the
regulation of CD4
+ lymphocyte numbers, a question presently
being addressed in a separate manuscript (unpublished observa-
tions). CD4
+ lymphocyte numbers were not found to correlate
with CXCR4
+ lymphocyte numbers or CCR5
+ lymphocyte
numbers individually or in combination with any parameters of
disease being investigated in these HIV-1 infected subjects, and
this suggests that although these chemokine receptors participate
during HIV-1 entry, they do not participate in the pathologic
decrease in CD4
+ lymphocytes.
It was previously demonstrated that early in disease, 89%
HIV-1 infected subjects have detectable antibody that is reactive
with a1PI [31]. Two monoclonal antibodies (1C1 and 3F5)
which bind a conformationally determined epitope near the C5
domain of gp120 were found to also bind human a1PI [32]. To
examine the possibility that antibodies reactive with a1PI might
participate in the depletion of active a1PI, IgG-a1PI immune
complexes were measured in all samples with sufficient residual
volume. Of 22 HIV-1 infected and 21 HIV-1 uninfected
individuals tested, 8 were found to be positive for detectable
IgG-a1PI immune complexes, and all 8 were HIV-1 infected
subjects. Significantly, IgG-a1PI immune complexes were
correlated with CD4
+ lymphocyte numbers (r
2=0.822,
p.0.05, n=8) and with serum inactive a1PI concentration
(r
2=0.988, p.0.05, n=8) (Fig. 1B).
Figure 1. Correlation between a1PI, IgG-a1PI immune complexes, and CD4
+ lymphocytes in HIV-1 infected subjects. (A) In subjects
with .220 CD4 cells/ml, CD4
+ lymphocyte levels correlate with active a1PI (r
2=0.927, p,0.0001, n=26). CD4
+ lymphocyte levels also correlate with
inactive a1PI, (r
2=0.906, p,0.0001, n=26). Subjects receiving protease inhibitor therapy are depicted by red squares. All other subjects are depicted
by black circles. In the 9 subjects with ,220 CD4 cells/ml, no correlation was found to exist between CD4
+ lymphocyte levels and active a1PI. Non-
linear regression was performed using a 3 parameter Sigmoid curve with power of test a=0.05. In this population, all variables were found to have
normality and constant variation. (B) In 8 of 35 subjects, IgG-a1PI immune complexes were detected and were correlated with CD4
+ lymphocyte
levels (r
2=0.822, p=0.05) and with inactive a1PI (r
2=0.988, p,0.0001).
doi:10.1371/journal.pone.0031383.g001
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It was hypothesized that anti-gp120 mediated depletion of
active a1PI might be pathognomonic for HIV-1-induced AIDS. If
true, this would suggest that chimpanzee a1PI differs from human
a1PI since HIV-1 infected chimpanzees survive infection and
regain normal numbers of CD4
+ lymphocytes [33]. Sequence
comparison revealed that other than the known polymorphisms,
human a1PI differs from chimpanzee a1PI by a single amino acid
(aa 385) caused by a single nucleotide change (NCBI accession
numbers BT019455 and XP_522938), and this variant amino acid
lies in the a1PI region homologous to gp120. To determine
whether this sequence difference influences the binding of anti-
gp120 to a1PI, sera were compared from 18 HIV-1 uninfected
humans and 20 HIV-1 uninfected chimpanzees.
In contrast to chimpanzee a1PI, binding of both 1C1 (data not
shown) and 3F5 to human a1PI was elevated 8- to 14-fold above
background in 6 repeat measurements (p,0.001) (Fig. 2A).
Negative control monoclonal antibody a70 which reacts with the
V3-loop of gp120 failed to bind human a1PI consistent with
previous findings [31], and there was no difference between
binding of a70 to human or chimpanzee sera (p=0.6). The
markedly greater affinity for 3F5 exhibited by serum a1PI in two
human subjects suggests that the epitope of a1PI recognized by
3F5 may be phenotypically determined. Even when these two
subjects were omitted from the comparison, the statistical
difference between binding of 3F5 to human versus chimpanzee
a1PI was maintained (p,0.001).
None of the sera from 20 HIV-1 uninfected chimpanzees, nor
sera collected from 2 chimpanzees post-HIV-1 inoculation, had
evidence of detectable IgG-a1PI immune complexes (Fig. 2B).
The HIV-1 inoculated chimpanzees were confirmed to be HIV-1
infected, but to have normal numbers of CD4
+ lymphocytes
(personal communication, Dr. P.N. Fultz) [34]. In addition,
despite the presence of anti-gp120, there was no evidence of IgG-
a1PI immune complexes in 12 rhesus macaques (median active
a1PI=36 mM) following immunization with simian/human im-
munodeficiency virus (SHIV 89.6) gp120 or gp140, or in 3
macaques infected with SHIV (median difference between pre-
and post-immunization, A490nm=0.08). Extensive in vitro ELISA
and Western Blot analyses failed to demonstrate bi-molecular
complexes between gp120 and a1PI which rules out the possibility
that anti-gp120 association with a1PI was mediated by gp120.
Further, the absence of detectable IgG-a1PI immune complexes in
sera from HIV-1 infected chimpanzees suggests that gp120 and
a1PI are not associated by aggregation in sera.
Consistent with previous evidence, the serum concentration of
active a1PI in HIV-1 subjects (median 18 mM) was significantly
below normal (median 26 mM, p,0.001) (Fig. 2C) and inactive
a1PI (median 19 mM), was significantly above normal (median
4 mM, p,0.001) (Fig. 2D) [31]. In contrast to humans, active
a1PI concentration in sera collected from the 2 chimpanzees post-
HIV-1 inoculation (median 39 mM) were not different from
normal human or chimpanzee sera (median 35 mM, p=0.810)
(Fig. 2E).
To determine whether a1PI becomes inactivated after com-
plexing with the 3F5 anti-gp120 monoclonal antibody, 3F5 was
incubated with sera samples from five healthy HIV-1 uninfected
subjects. In comparison to control untreated sera, a1PI activity was
significantly diminished to the same degree in all 3F5-treated sera
(mean difference=5.860.5 mM, p,0.001) (Fig. 2E).
To determine whether 3F5 anti-gp120 is the same antibody that
produces IgG-a1PI immune complexes in HIV-1 infected subjects,
a1PI activity was quantitated in 22 sera in the presence or absence
of added HIV-1 virions in a blinded manner. Sera from 13 HIV-1
infected subjects with undetectable HIV RNA and .220 CD4
cells/ml, 5 of whom had detectable IgG-a1PI immune complexes,
and 9 HIV-1 uninfected subjects were incubated with an
inactivated simian immunodeficiency virus (SIV) chimera which
expresses the HIV envelope (AT-2 SHIV) [35,36]. The a1PI
activity increased in 5 of 22 sera incubated with AT-2 SHIV, and
these 5 sera were the same 5 sera from HIV-1 infected subjects
that were found to have detectable IgG-a1PI immune complexes
suggesting the a1PI-inactivating factor adsorbed by the virions
might have been anti-gp120 (Table 3). In contrast, active a1PI
was unchanged in all 9 HIV-1 uninfected sera and in all 8 of the
sera from HIV-1 infected subjects lacking detectable IgG-a1PI
immune complexes. HIV-1 infected subjects with IgG-a1PI
immune complexes were found to have significantly lower CD4
counts (median=210) than subjects without a1PI-IgG immune
complexes (median=327, p=0.045).
To demonstrate the specificity of the inactivating factor
adsorbed by AT-2 SHIV, virions were pre-complexed with 3F5
monoclonal anti-gp120 prior to incubation with sera. By ELISA, it
was determined that incubating AT-2 SHIV (30 mg p24) with
20 ng 3F5 in 100 ml for 45 min at 23uC results in a binding ratio
of 50 ng 3F5/mg p24. After pre-complexing with 3F5, AT-2 SHIV
Table 2. Regression analysis of CD4
+ and absolute lymphocyte numbers in HIV-1 infected subjects.
Independent Variables
a
HLECS
+ Ly CXCR4
+ Ly Active a1PI CXCL12
93±69 cells/ml
n=21
1485±531 cells/ml
n=26
19±8 mM
n=26
280±53 pM
n=22
Dependent Variables Multilinear Regression
b
CD4
+ Ly
5036210 cells/ml, n=26
p=0.011 p=0.695 p,0.001 p=0.766 r
2=0.64, p=0.003, n=20
Total Ly
18826546 cells/ml, n=26
p=0.596 p,0.001 p=0.16 p=0.02 r
2=0.80, p,0.001, n=20
aValues for independent and dependent variables represent mean 6 standard deviation. HLECS
+ lymphocytes and CXCR4
+ lymphocytes in the lymphocyte gate (Ly)
were quantitated using flow cytometry. Active a1PI and CXCL12 were quantitated in serum as described.
bMultilinear regression was performed to determine the relationship of the dependent variables to the independent variables using power of test a=0.05. Dependent
variables were considered to be significantly related to the independent variable if they contributed significantly to the multilinear regression (p,0.05). In this
population sample, variables were found to have constant variance and normality.
doi:10.1371/journal.pone.0031383.t002
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had no effect on a1PI activity (Table 3). These results
demonstrate that 3F5 anti-gp120 in patient sera is the principal
factor responsible for inactivating a1PI. Further, these results
indicate that, as would be anticipated, anti-gp120 in patient sera
has greater affinity for gp120 than for a1PI.
Discussion
Herein is shown that active a1PI counterbalances HLECS in
regulating CD4
+ lymphocyte blood levels in HIV-1 infected and
uninfected subjects. In contrast to HIV-1 uninfected subjects, two
important differences in the HIV-1 infected population with .220
CD4 cells/ml are notable; 1) the dependence of absolute
lymphocyte numbers on CXCL12, and 2) the lack of dependence
of CD4
+ lymphocytes on the number of CXCR4
+ lymphocytes.
Since there are fewer CXCR4
+ lymphocytes in HIV-1 infected
subjects (73%) and even fewer CD4
+ lymphocytes (49%), yet no
difference in serum CXCL12 or HLECS
+ lymphocytes, this
suggests a flaw in the interaction between CXCR4 and CXCL12,
presumably in bone marrow, that results in production of fewer
CXCR4
+ lymphocytes despite the presence of sufficient CXCL12.
Table 3. HIV-1 patient serum antibodies that bind the 3F5-recognized gp120 epitope are the same antibodies that bind and
inactivate a1PI.
Subject IgG-a1PI (A490 nm)
a Active a1PI+buffer Active a1PI+SHIV Active a1PI+3F5-complexed SHIV
1 0.9955 25 mM3 0 mM2 4 mM
2 1.0520 11 mM1 9 mM1 0 mM
3 1.1305 15 mM3 0 mM1 3 mM
4 1.5515 9 mM1 7 mM9 mM
5 2.6410 5 mM8 mM5 mM
aSera were selected from HIV-1 infected subjects with undetectable HIV RNA (n=13) or from HIV-1 uninfected subjects (n=9). Of the 22 sera tested, only 5 exhibited
increased a1PI activity in the presence of SHIV, and these 5 were the only specimens that were also positive for IgG-a1PI immune complexes (A490nm.0.5). Immune
complexes were undetectable in the other 17 sera and none of those sera exhibited a difference in a1PI activity in the presence of SHIV (Mean difference=0.7 mM6
1 mM).
doi:10.1371/journal.pone.0031383.t003
Figure 2. Binding of anti-gp120 to human, but not chimpanzee a1PI. (A) Monoclonal antibody 3F5 (5 mg/ml) binding to a1PI in sera from 18
HIV-1 uninfected humans and 20 HIV-1 uninfected chimpanzees was measured using ELISA. Antibody bound (A490 nm) was normalized for the active
a1PI concentration in each specimen and is represented as A490nm/[a1PI (mM)]. Representative data from 6 measurements are depicted. Bars
represent median values. Median 3F5 bound to human a1PI was 0.12 and to chimpanzee a1PI was 0.02. Negative control monoclonal antibody a70
(10 mg/ml) yielded A490nm=0.02 when incubated with a1PI at concentrations varying between 3 mM and 540 mM. There was no difference in binding
of a70 to human or chimpanzee sera (p.0.6). (B) IgG-a1PI immune complexes (A490 nm) were measured in sera from HIV-1 uninfected humans (n=9),
HIV-1 infected humans (n=35), HIV-1 uninfected chimpanzees (n=20), HIV-1 challenged chimpanzees (n=2), rhesus monkeys pre-immunization and
2 time points post immunization (n=12), and rhesus monkeys pre- and post-infection (n=3). There was no significant difference in rhesus monkeys
pre- and post-immunization, pre-and post-infection. Representative data of triplicate measurements are depicted. (C) Active a1PI was measured in
HIV-1 uninfected humans (26 mM, n=20), HIV-1 infected humans (18 mM, n=35), HIV-1 uninfected chimpanzees (35 mM, n=20), HIV-1 challenged
chimpanzees (39 mM, n=2), rhesus monkeys pre-immunization and 2 time points post immunization (36 mM, n=12), and rhesus monkeys pre- and
post-infection (43 mM, n=3). There was no significant difference in rhesus monkeys pre- and post-immunization, pre-and post-infection. Bars
represent median values. (D) Inactive a1PI was measured in HIV-1 uninfected (4 mM, n=20) and HIV-1 infected humans (19 mM, n=35). Bars represent
median values. (E) Active a1PI levels in sera from 5 HIV-1 infected subjects after incubation with either medium (control) or with monoclonal antibody
3F5.
doi:10.1371/journal.pone.0031383.g002
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small, CXCL12 might systemically influence the number of
CXCR4
+ lymphocytes by inducing their egress from blood into
tissue. The increased CXCL12, HLECS
+ lymphocytes, and CD4
+
lymphocytes in the presence of active liver disease in 11 HIV-1
infected patients suggests a potential regulatory axis between the
liver and hematopoietic tissue that may include additional
unknown factors.
In the HIV-1 uninfected population, CD4
+ lymphocyte
numbers were correlated with three factors including serum active
a1PI, HLECS
+ and CXCR4
+ lymphocyte numbers. Since HLECS
and CXCR4 are known to participate in regulating hematopoiesis,
this suggests a1PI, HLECS and CXCR4 regulate the number of
CD4
+ lymphocytes. Because CD4
+ lymphocyte numbers were
correlated with serum active a1PI concentration with such a high
degree of significance in HIV-1 infected subjects with .220 CD4
cells/ml( r
2=0.927, p,0.0001), it can be concluded that there is a
direct regulatory link between active a1PI and CD4
+ lymphocyte
numbers although this doesn’t show causality. Because we have
previously demonstrated that a1PI augmentation therapy pro-
duced an increase in the number of circulating CD4
+ lymphocytes
in HIV-1 infected and uninfected subjects, it can be concluded
that a1PI regulates the number of CD4
+ lymphocytes in blood
[13]. Since active a1PI regulates CD4
+ lymphocyte numbers, yet
HLECS
+ and CXCR4
+ lymphocyte numbers appear not to
contribute to regulation in the HIV-1 infected subjects, it can be
concluded that active a1PI is the rate limiting factor for regulating
CD4
+ lymphocyte numbers in HIV-1 infected subjects. Whether
the influence of a1PI on hematopoiesis occurs in bone marrow, the
thymus, or elsewhere is currently being investigated.
Three distinct activities of a1PI are performed by moieties
within the carboxyl terminal of the protein: (1) inhibition of soluble
HLEG mediated by active site residue Met
358; disruption of this
activity results in emphysema and respiratory-related infections; (2)
induction of receptor polarization and cell migration mediated by
a1PI residues
370 FVFLM
374 [19]; evidence suggests that this
domain stimulates cell motility and is responsible for the binding of
HLECS- a1PI complexes to members of the LDL receptor family
[37,38]; and (3) binding of a1PI to antibodies reactive with HIV-1
gp120 [31]; functional a1PI deficiency in HIV-1 disease was
previously shown to be caused primarily by IgG-a1PI immune
complex formation, not by impaired synthesis, proteolysis, or
oxidation [31]. IgG-a1PI immune complexes were not detected in
all HIV-1 infected subjects, and this may be due to the presence of
immunoglobulin subclasses other than IgG, the inability to capture
a1PI bound in immune complexes with high IgG content, or their
absence in some individuals [39].
The gp120 epitope recognized by the 1C1 and 3F5 antibodies is
considered to be conformation-dependent [40]. The gp120
peptide immunogen used to raise 1C1 and 3F5 (
471GGG-
DMRDNWRSELYKYKVVK
490) [41] contains both an a-helix
(aa 476–484) and linear strand (aa 485–490) (Fig. 3A,B), but other
epitope determinants of the antibodies are not known. Human
a1PI, which also binds 1C1 and 3F5, contains (Fig. 3C,D), the
gp120-homologous sequence (
369PFVFLMIDQNTKSPLFMG-
KVV
389) that folds to form a two-stranded antiparallel b-sheet
lying at the base of a cleft (4 A ˚ deep by 20 A ˚ long by 5 A ˚ wide)
topped by two a-helices (aa 27–44 and 259–277) in a smaller, but
similar configuration as the antigen-binding cleft of MHC (10 A ˚
deep by 25 A ˚ long by 10 A ˚ wide) [42]. At the end of the first of
these a-helices is the N-linked mannose-containing oligosaccharide
that confers structural polymorphism to a1PI (N-linkage at Asn-46)
[43]. In the center of the b-sheet that lies in the cleft is Met-385
which distinguishes human from chimpanzee a1PI (equivalent
residue=Val-385). Although the function of this cleft is not
known, a sequence in the center of the b-sheet formation
(
370FVFLM
374) is homologous to the fusion domain of HIV-1
gp41 [21], and this sequence has been implicated in binding to
members of the LDL receptor family and in stimulating cell
migration [44] [37].
Within the a1PI protein, the sequence
386GKVV
389 lies within
5A ˚ of Met-385 and Asn-46 with its N-linked oligosaccharide in a
space occupying 5 A ˚ by 5 A ˚ by 5 A ˚. In the same relative
orientation as in a1PI, the gp120 sequence
486YKVV
489 lies within
5A ˚ of Met-95 and 8 A ˚ of Asn-234 with its N-linked mannose-
containing oligosaccharide [45] in a space of dimensions 5 A ˚ by
5A ˚ by 8 A ˚. Significantly, the gp120 Asn-234 is invariant [46].
The N-linked oligosaccharide of a1PI Asn-46 confers polymor-
phism, and our observation that 3F5 binding to a1PI in 2 control
sera is much greater than in the other 16 control sera (Fig. 3a)
suggests this oligosaccharide may reside within the 3F5 epitope.
Thus, these spatial analyses suggest that the 3F5 conformational
epitope occupies a space approximately 5 A ˚ by 5 A ˚ by 8 A ˚ which
includes KVV, M, N, and the N-linked oligosaccharide. The
dimensions of this proposed conformational epitope are consistent
with previously characterized 8 A ˚ by 7 A ˚ antigens that contain
oligosaccharide determinants [47].
Comparison of the amino acid sequences of human a1PI, HIV-
1, HIV-2, SIV (including SIVCPZ), HTLV-1, and HTLV-2 reveals
that all share homology with the hydrophobic core of the fusion
domain of HIV-1 gp41 (LFLGFL), but only HIV-1 gp120 shares
homology with the C-terminal domain of a1PI [31]. This
observation is consistent with the species-specific differences in
disease caused by the corresponding immunodeficiency viral
infections. For example, neither SIV nor HTLV produce AIDS in
their natural hosts [48]. SIV causes CD4 depletion in some simian
species, but the progression to AIDS is disproportionately faster
than in HIV-1 infection of humans. HIV-2 infection may induce
AIDS, however, the frequency of AIDS incident to HIV-2
infection is 20-fold lower than for HIV-1, suggesting a variant
mechanism of disease progression [49]. That antibodies reactive
with a1PI are produced in response to a homologous sequence
unique to HIV-1 suggests this immune reaction distinguishes HIV-
1 infection from other retroviral infections. Importantly, a single
amino acid differentiates chimpanzee a1PI from human a1PI, and
this difference is in the HIV-1 gp120 homologous domain, perhaps
explaining the lack of progression to AIDS in HIV-1 infected
chimpanzees [33].
Molecular mimicry by viruses accommodates non-disruptive
incorporation into its natural host thereby facilitating reproduction
and avoiding immune clearance. Cross-species virus infection
produces a situation in which molecular mimicry is less efficient
thereby leading to an inflammatory response and immune
recognition. Such situations can secondarily produce autoimmu-
nity. Considering that the proteinases and proteinase inhibitors
that maintain homeostasis are species-specific, the variable disease
sequelae caused by SIV infection in variant monkey species could
be due to the interaction of SIV or anti-SIV with a variety of
homologous proteinases and proteinase inhibitors involved in
homeostasis, for example, coagulation and complement proteins.
Similarly, the variation in onset and course of HIV-1 and HIV-2
disease in man could be caused by differences in the interaction of
HIV-1, HIV-2, anti-HIV-1, or anti-HIV-2 with various blood
components involved in homeostasis. The binding of HIV-1-
specific antibodies to human proteins is well-established, for
example, Mac-1 [50], cardiolipin [51], inter-a-trypsin inhibitor
[52], and MHC Class II [53]. In one study, 49 of 150 HIV-1
infected subjects were found to have autoantibodies reactive with
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suggests that inactivation of a1PI by anti-gp120 is the fundamental
reason CD4
+ lymphocytes fail to be replenished and that a1PI
augmentation therapy can overcome this autoimmune phenom-
enon and re-establish normal levels of CD4
+ lymphocytes [13].
The ability of HIV-1 virions to liberate a1PI from anti-gp120
antibodies is not surprising since HIV-1, not a1PI, is the
immunogen. The competitive advantage of HIV-1 for binding to
anti-gp120 provides a unique method for therapeutically liberating
a1PI by blocking autoimmune antibodies. In this manner, humans
might co-exist with HIV-1, as chimpanzees do, without developing
AIDS. Theoretically, modification of candidate HIV-1 vaccines so
that antibodies that react with human proteins are avoided
altogether provides a means to develop a vaccine that protects
against AIDS as opposed to the current approach to develop a
vaccine that protects against HIV-1 infection.
Materials and Methods
Ethics Statement
Collection of blood from research subjects was approved by the
institutional review board of Cabrini Medical Center. Written
informed consent was obtained from all subjects prior to
participation in these studies. Residual sera from chimpanzees
were purchased or approved for use by the LEMSIP IACUC.
Human subjects
After obtaining informed consent, blood was collected from 30
HIV-1 seronegative, healthy adults, 14 males and 16 females, and
from 39 HIV-1 seropositive adults attending clinic, 37 males and 2
females. Two of the HIV-1 uninfected individuals were healthy
adults with the inherited version of a1PI deficiency (PIZZ) and
exhibited 41% and 42% CD4
+ lymphocytes (reference
range=34%–58%). HIV-1 infected individuals with malignancies
(n=4) were omitted from analyses of CD4
+ lymphocyte levels and
are being evaluated separately. Of the remaining 35 HIV-1
infected individuals included in the study, 11 had evidence of
active liver disease.
Rhesus serum (Macaca mulatta)
Adult monkeys were immunized with SHIV or were infected
with SHIV 89.6 as described in a previous report [55]. Residual
sera from 12 immunized and 3 infected monkeys were obtained
from Dr. D.C. Montefiori with approval from the Duke University
Medical Center IACUC.
Chimpanzee serum (Pan troglodytes)
Residual sera from 20 uninfected HIV-1 adult chimpanzees, 10
males and 10 females, were purchased from YERKES Regional
Primate Center of Emory University. Residual sera from 2
chimpanzees collected pre- and 42 months post-HIV-1 challenge
Figure 3. Corresponding conformation at the 3F5-recognized epitope in a1PI and CD4-complexed HIV-1 gp120. HIV-1 gp120 is
depicted from two perspectives (A,B) with green representing two a-helices (aa 100–115 and 476–484). The gp120 peptide immunogen used to raise
1C1 and 3F5 (aa 471–490) is located at the C-terminus of gp120, and the linear segment
486YKVV
489 is depicted in red along with Met95 and the
oligosaccharide-linked segment
234NGT
236, all of which are within 8 A ˚ of the conformational epitope. The gp120-homologous domain in a1PI is also
located at the C-terminus of the protein, and is depicted from two perspectives (C,D) with violet representing the antiparallel b-sheet strand at the
base of the cleft (aa 369–389), and green representing the a-helices that form the mouth of the cleft (aa 27–44 and 259–277). Met-385, which
distinguishes human from chimpanzee a1PI, is depicted in red along with the segment
386GKVV
389, the oligosaccharide, and oligosaccharide-linked
segment
46NST
48. The HLEG-reactive site Met-358, is depicted in yellow for orientation. Structures for human a1PI (1HP7) and CD4-complexed HIV-1
gp120 (1RZJ) from the NCBI Molecular Modeling Database (MMDB) were analyzed using Cn3D software. Small carbohydrate structures, depicted in
multiple colors, were associated with 1RZJ in MMDB, and the three associated with 1HP7 were added using Adobe Photoshop.
doi:10.1371/journal.pone.0031383.g003
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obtaining approval from the LEMSIP IACUC [34,56]. One
chimpanzee was inoculated IV with cell-free HIV-DH12 [57].
The other chimpanzee was inoculated twice via the cervical os
with HIV-infected peripheral blood cells from a chimpanzee
infected with HIV LAI/IIIB and once IV with cell-free HIV-LAI/
IIIB [34]. Both chimpanzees were previously confirmed to be
infected and to have normal CD4
+ lymphocyte levels [34].
Flow cytometric analysis
Surface staining for markers on cells was performed by
incubating whole blood for 15 min at 23uC with anti-CD4-FITC,
anti-CXCR4-PE, anti-CCR5-PE, isotype controls (BD Bioscienc-
es, San Diego, CA). Cells were subsequently stained to detect
HLECS by incubating whole blood for an additional 15 min at
23uC with rabbit anti-HLE (Biodesign, Kennebunkport, ME) or
negative control rabbit IgG (Chemicon, Temecula, CA) which had
been conjugated to Alexa Fluor 647 (Molecular Probes, Eugene,
OR). After lysing red blood cells and washing, stained cells were
fixed. At least 10,000 cells from each sample were acquired using a
FACSCalibur flow cytometer. Markers on cells in the lymphocyte
gate were quantitated, and CD4
+ cells in the lymphocyte gate were
compared with measurements obtained from an outside contractor
to validate gating. In all cases CD4
+ lymphocyte numbers were
within 95% agreement between the two laboratories. Cell staining
was analyzed using CellQuest (BD Biosciences) or FlowJo software
(Tree Star, Inc., Ashland, OR).
Quantitation of serum CXCL12, a1PI, a2M, and anti-a1PI
Serum CXCL12 was measured in duplicate using an ELISA kit
according to the manufacturer (R&D Systems, Minneapolis, MN).
Total serum a1PI protein was determined in 8 serial serum dilutions
by ELISAusing previously describedmethods with the modification
that serum dilution buffers contained 10 mM EDTA [58]. Active
and inactive fractions of a1PI in once-thawed sera were detected
using inhibition of porcine pancreatic elastase (PPE, Sigma, St.
Louis, MO) as previously described [58] with the modification that
end-point, rather than kinetic, analysis was measured [58]. IgG-
a1PI immune complexes were measured in triplicate in phosphate
buffered saline pH 7.2 by incubating sera in wells of a microtiter
plate pre-coated with chicken anti-human a1PI IgG (OEM
Concepts, Toms River, NJ) as previously described [31], and
captured a1PI-complexed IgG was detected using peroxidase-
conjugated rabbit anti-human IgG (Sigma), a reagent that was
confirmed to react with chimpanzee and rhesus macaque IgG.
Serum from HIV-1 uninfected subjects that had been collected into
tubes containing clot activating additive were excluded from
immune complex analysis because of buffer incompatibility.
Binding of anti-gp120 antibody to a1PI
Human or chimpanzee sera from HIV-1 uninfected subjects were
diluted 1:10 in 200 ml phosphate buffered saline containing, 5% fish
gelatin and 10 mM EDTA to which was added 10 ml containing
1 mg murine monoclonal antibodies 1C1 (Repligen, Inc., Cam-
bridge, MA) or 3F5 (hybridoma culture supernatant, 0085-P3F5-
D5-F8, a generous gift from Dr. Larry Arthur, NCI-Frederick).
Monoclonal 1C1 and 3F5 were raised against a peptide immunogen
from the HIV-1 gp120 C5 domain (aa 471–490, GGGDMR-
DNWRSELYKYKVVK) [40] and bind a conformational epitope
[32]. Alternatively, sera were incubated with 10 mlc o n t a i n i n g2mg
negative control antibody Clone a70 (ICN Biochemicals, Aurora,
OH) reactive with the V3 loop of HIV-1 gp120. Immune complexes
that were formed by adding anti-gp120 monoclonal antibodies to
humanorchimpanzeeserawerecapturedbyincubatingserainwells
of a microtiter plate pre-coated with chicken anti-human a1PI IgG
(OEM Concepts). Binding was detected using horse radish
peroxidase-conjugated rabbit anti-mouse IgG (Sigma) followed by
substrate, orthophenylene diamine HCl.
Inactivated virus adsorption of antibodies from a1PI
The AT-2-inactivated SHIV preparation used in this study was
generously provided by Jeff Lifson, Julian Bess, and Larry Arthur
of the AIDS Vaccine Program (SAIC-Frederick, National Cancer
Institute at Frederick, Frederick, MD, USA). Chemically inacti-
vated non-infectious virus with conformationally and functionally
intact envelope glycoproteins was produced by treatment with AT-
2 as described [35,36]. The SHIV89.6 virus was produced from
the CEM X 174 (T1) cell line [35]. Virus content of purified
concentrated preparations was determined with an antigen
capture immunoassay for capsid protein (AIDS Vaccine Program).
Virus stocks were diluted in 1% BSA (Intergen, New York, NY,
USA) in Dulbecco’s PBS and stored as aliquots (3 mg capsid
protein/ml) at 280uC until use.
To determine the adsorption of anti-gp120 antibodies from
a1PI, AT-2 SHIV (3 mg/ml) or dilution buffer (Dulbecco’s PBS
+1% BSA) were added to an equal volume of serum and incubated
for 30 min at 23uC prior to measuring a1PI activity. To
demonstrate the specificity of antibody adsorption, AT-2 SHIV
virions (5.5 mg/120 ml) were pre-incubated with 3F5 monoclonal
anti-gp120 (10.5 mg/500 ml) or dilution buffer (500 ml) for 60 min
at 23uC prior to with serum. Unbound 3F5 was removed by
centrifugation of AT-2 SHIV virions at 14,000 g for two hrs, and
virions were resuspended in 120 ml Tris-buffered saline, pH7.8,
containing 10 mM EDTA.
Statistical Analysis
Least squares linear and multiple linear regression were
performed using SigmaPlot. Unless other stated, Measurements
are presented as mean 6 standard deviation for absolute
lymphocyte counts, CD4
+, CXCR4
+, CCR5
+, and HLECS
+
lymphocytes, as well as serum concentrations of CXCL12, total
a1PI, active a1PI, inactive a1PI, IgG-a1PI immune complexes, and
3F5 anti-gp120 binding to human and chimpanzee a1PI. Absolute
lymphocyte counts, CXCR4
+, and CCR5
+ lymphocytes were
normally distributed, and means were compared. HLECS
+
lymphocytes, and serum concentrations of CXCL12, active a1PI,
inactive a1PI, IgG-a1PI immune complexes, and 3F5 anti-gp120
binding to human and chimpanzee a1PI were not normally
distributed, and medians were compared. CD4
+ lymphocytes were
normally distributed in the HIV-1 uninfected subjects, but not
normally distributed in the HIV-1 infected subjects, and medians
were compared. Means were compared using Student’s t-test, and
medians were compared using the Mann-Whitney Rank Sum Test.
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